| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DRD5 |
| Uniprot No | P21918 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-477aa |
| 氨基酸序列 | MLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLLIIWTLLGNVLVCAAIVRSRHLRANMTNVFIVSLAVSDLFVALLVMPWKAVAEVAGYWPFGAFCDVWVAFDIMCSTASILNLCVISVDRYWAISRPFRYKRKMTQRMALVMVGLAWTLSILISFIPVQLNWHRDQAASWGGLDLPNNLANWTPWEEDFWEPDVNAENCDSSLNRTYAISSSLISFYIPVAIMIVTYTRIYRIAQVQIRRISSLERAAEHAQSCRSSAACAPDTSLRASIKKETKVLKTLSVIMGVFVCCWLPFFILNCMVPFCSGHPEGPPAGFPCVSETTFDVFVWFGWANSSLNPVIYAFNADFQKVFAQLLGCSHFCSRTPVETVNISNELISYNQDIVFHKEIAAAYIHMMPNAVTPGNREVDNDEEEGPFDRMFQIYQTSPDGDPVAESVWELDCEGEISLDKITPFTPNGFH |
| 预测分子量 | 52,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DRD5重组蛋白的3篇代表性文献概览：
1. **《Expression and characterization of the human D5 dopamine receptor in mammalian cells》**
- **作者**: Sunahara RK et al.
- **摘要**: 该研究在哺乳动物细胞(HEK293)中成功重组表达了人源DRD5受体，并证实其通过激活腺苷酸环化酶介导cAMP信号通路。研究优化了受体膜定位条件，并验证了多巴胺及其激动剂对重组DRD5的特异性激活作用。
2. **《Purification and functional reconstitution of the human D5 dopamine receptor》**
- **作者**: Javitch JA et al.
- **摘要**: 报道了利用杆状病毒-昆虫细胞系统高效表达DRD5重组蛋白，通过亲和层析技术纯化获得高纯度受体蛋白。功能重建实验显示重组DRD5能够与Gαs蛋白偶联，为体外药理学研究提供了可靠模型。
3. **《Structural insights into ligand recognition by the dopamine D5 receptor-G protein complex》**
- **作者**: Zhang Y et al.
- **摘要**: 通过冷冻电镜技术解析了重组DRD5与多巴胺及Gαs蛋白复合物的三维结构，揭示了DRD5配体结合口袋的独特氨基酸残基排列，阐明了其相较于DRD1受体的高基础活性分子机制。研究使用CHO细胞系进行重组蛋白表达。
Dopamine receptor D5 (DRD5) is a member of the dopamine receptor family, which belongs to the G protein-coupled receptor (GPCR) superfamily. Specifically, DRD5 is classified under the D1-like receptor subfamily, alongside DRD1. and signals primarily through the activation of adenylate cyclase via Gαs proteins, leading to increased intracellular cyclic AMP (cAMP) levels. It shares structural homology with DRD1 but exhibits a higher basal activity and sensitivity to dopamine, suggesting distinct regulatory roles in the central nervous system (CNS). DRD5 is implicated in various physiological processes, including cognition, emotional regulation, and motor control, and has been linked to neuropsychiatric disorders such as schizophrenia, Parkinson’s disease, and attention-deficit/hyperactivity disorder (ADHD).
Recombinant DRD5 protein is engineered for in vitro studies to elucidate its signaling mechanisms, ligand interactions, and structural dynamics. Produced using heterologous expression systems like mammalian cells (e.g., HEK293 or CHO cells) or insect cells, the recombinant protein retains post-translational modifications crucial for functionality. Purification typically involves affinity chromatography tags (e.g., His-tag) followed by validation via Western blot or ligand-binding assays. Researchers utilize recombinant DRD5 to screen therapeutic compounds targeting dopamine pathways, investigate receptor dimerization, or study mutations associated with disease phenotypes. Its application extends to structural biology, aiding in cryo-EM or X-ray crystallography studies to resolve receptor-ligand complexes. Despite challenges in stabilizing the protein due to GPCR instability, advancements in expression systems and solubilization techniques continue to enhance its utility in both basic and translational neuroscience research.
×
